July 26 (Reuters) - AstraZeneca said on Monday the European Medicines Agency (EMA) had recommended approving a medicine from its Alexion unit for treating a rare, deadly blood disorder in children and adolescents aged up to 18 years.

The drugmaker, which recently completed its $39 billion buyout of U.S.-based Alexion, said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria by the human medicines committee of the EMA. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)